Verona Pharma PLC (VRNA)
28.76
+1.12
(+4.05%)
USD |
NASDAQ |
Sep 27, 16:00
28.76
0.00 (0.00%)
After-Hours: 20:00
Verona Pharma Research and Development Expense (Annual): 17.22M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.22M |
| December 31, 2022 | 49.28M |
| December 31, 2021 | 79.41M |
| December 31, 2020 | 44.50M |
| December 31, 2019 | 42.42M |
| December 31, 2018 | 24.48M |
| December 31, 2017 | 32.05M |
| December 31, 2016 | 5.579M |
| December 31, 2015 | 10.77M |
| Date | Value |
|---|---|
| December 31, 2014 | 4.101M |
| December 31, 2013 | 2.732M |
| December 31, 2012 | 2.707M |
| December 31, 2011 | 1.465M |
| December 31, 2010 | 1.776M |
| December 31, 2009 | 1.528M |
| December 31, 2008 | 1.286M |
| December 31, 2007 | 1.499M |
| December 31, 2006 | 0.2665M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.22M
Minimum
2023
79.41M
Maximum
2021
46.57M
Average
44.50M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 31.19M |
| TC BioPharm (Holdings) PLC | 9.670M |
| Autolus Therapeutics PLC | 130.48M |